Vertex's Casgevy wins pediatric approval, United Therapeutics buys Thymmune for up to $300M, plus deals from Insilico, Fosun and Abbisko.
July 2, 2026 10:10 AM EDT
News Briefing
Vertex's sickle cell therapy approved for kids; United Therapeutics buys startup
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
BridgeBio gets funding for drug launch; United buys into cell therapy
FDA expands Casgevy approval to children 2 years and older with sickle cell disease
FDA Approves Sickle Cell Gene Therapy for Young Kids
Roche drug sets new standard for KRAS-driven lung cancer
Vertex Reports CASGEVY Data Showing Sustained Benefits In Children With Sickle Cell Disease And Beta Thalassemia
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell…
Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded…
Cartesian’s $150M financing; Editas Medicine’s money moves
Angitia halts a Phase 3 disc-disease trial, Abivax prices an upsized $800M offering, and AlzeCure lands a $2.2B NeuroRestore deal…
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
